
FDMT Stock Forecast & Price Target
FDMT Analyst Ratings
Bulls say
4D Molecular Therapeutics is a biotechnology company focused on developing gene therapy treatments for a variety of diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Their portfolio of gene therapy product candidates has shown promising results in clinical trials, reducing technology risk and validating the potential for widespread use. However, there are risks associated with clinical trial outcomes and manufacturing challenges, which may impact the company's ability to bring these treatments to market and achieve peak sales forecasts.
Bears say
4D Molecular Therapeutics is a biotechnology company that has built a portfolio of promising gene therapy products for ophthalmology, cardiology, and pulmonology. However, the company faces potential competition from other emerging therapies and could face challenges in manufacturing its products, which could impact its financials and lower its potential for profitability. Additionally, there are risks associated with the success of its clinical trials and the need for additional financing, which could result in share dilution for shareholders. These factors contribute to the negative outlook for 4D Molecular Therapeutics's stock.
This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
FDMT Analyst Forecast & Price Prediction
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares